Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212597 | 0.93 | NTRK1 (0.49) | NTRK1EGFRCDK9CCNT1 | |
| SCHEMBL6237654 | 0.92 | KDM4E (0.42) | TBK1MARK3MARK4STK17ACDK1 | |
| SCHEMBL6242731 | 0.91 | MARK3 (0.40) | TBK1EGFRMARK3MARK4STK17A | |
| SCHEMBL6234855 | 0.91 | IGF1R (0.44) | TBK1MARK3MARK4STK17ACDK1 | |
| SCHEMBL6243731 | 0.90 | IGF1R (0.44) | TBK1MARK3MARK4STK17ACDK1 | |
| SCHEMBL6212762 | 0.89 | ALDH1A1 (0.49) | NTRK1MARK3MARK4STK17AHTR6 | |
| SCHEMBL6236421 | 0.88 | HTR6 (0.40) | TBK1MARK3MARK4STK17ACDK1 | |
| SCHEMBL6240858 | 0.88 | PAK4 (0.40) | MARK3STK17ACDK1HTR6 | |
| SCHEMBL6237567 | 0.87 | KDM4E (0.41) | TBK1EGFRMARK3MARK4STK17A | |
| SCHEMBL6243567 | 0.87 | TBK1 (0.43) | TBK1CDK9MARK3MARK4STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | TBK1 4758/4885NTRK1 4221/4885EGFR 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.